ERBB2 and neoplasm: Targeted antibody therapies such as the HER2/ErbB2 monoclonal antibody trastuzumab (Tz, Herceptin) poorly extravasate in the brain (requiring BBB opening methods)3,4 thus poorly affecting brain metastases even when peripheral tumours respond to Tz treatment5.